ProbioticStrong Evidence

Saccharomyces boulardii

A beneficial probiotic yeast (not a bacteria) that is naturally antibiotic-resistant — making it uniquely effective for antibiotic-associated diarrhea and C. difficile prevention.

What is Saccharomyces boulardii?

Saccharomyces boulardii is a non-pathogenic tropical yeast probiotic, genetically distinct from baker's yeast (S. cerevisiae), originally isolated from lychee and mangosteen fruit in Indochina. Its unique advantage as a probiotic is natural resistance to all antibacterial antibiotics.

Known Health Benefits

Prevents antibiotic-associated diarrhea
C. difficile prevention and recurrence reduction
Traveler's diarrhea support
Gut microbiome restoration post-antibiotics

How It Works

S. boulardii exerts therapeutic effects through multiple mechanisms. It secretes a 54 kDa serine protease that cleaves Clostridioides difficile toxin A and its intestinal receptor, directly blocking C. difficile pathogenesis. The yeast produces phosphatases that dephosphorylate bacterial endotoxins (lipopolysaccharides), reducing their inflammatory potency. S. boulardii stimulates secretory IgA production and upregulates brush border enzymes (sucrase-isomaltase, lactase), improving nutrient absorption. It releases polyamines (spermine, spermidine) that promote enterocyte maturation and enhance intestinal trophic responses. Anti-inflammatory effects occur through inhibition of NF-κB and MAP kinase pathways in intestinal epithelial cells, reducing IL-8 and TNF-α production. Unlike bacterial probiotics, S. boulardii is unaffected by concurrent antibiotic therapy, making it uniquely suited for use during antibiotic courses. It does not permanently colonize the gut and is cleared within 3–5 days after discontinuation.

What Research Says

A meta-analysis by McFarland (World Journal of Gastroenterology, 2010) of 27 RCTs with 5029 patients found S. boulardii reduced antibiotic-associated diarrhea risk by 52%. For C. difficile infection, Surawicz et al. (Clinical Infectious Diseases, 2000) demonstrated S. boulardii combined with standard antibiotics reduced recurrence by 50% compared to antibiotics alone. A Cochrane review (Goldenberg et al., 2017) confirmed S. boulardii's efficacy for preventing Clostridium difficile-associated disease. For traveler's diarrhea, Kollaritsch et al. (Infection, 1993) found S. boulardii reduced incidence by 29% in a large placebo-controlled trial of 3000 travelers. In acute pediatric diarrhea, Szajewska & Skórka (Alimentary Pharmacology & Therapeutics, 2009) found S. boulardii reduced duration by approximately 1 day.

Active Compounds

Saccharomyces cerevisiae var. boulardii (live yeast)

Forms & Bioavailability

Freeze-dried capsules (Florastor is the original brand)Sachet powderShelf-stable formulationsCombination formulas with bacterial probiotics

S. boulardii is a living yeast that achieves steady-state concentrations in the colon within 3 days of daily administration. It is not absorbed systemically but acts within the GI lumen. Being a yeast, it is inherently resistant to all antibacterial antibiotics but is killed by antifungal medications.

Dosage Guidance

Use CaseDosage
Antibiotic-associated diarrhea prevention250–500 mg (5–10 billion CFU)/day
C. difficile prevention/recurrence500 mg twice daily
Traveler's diarrhea prevention250–500 mg/day
Acute diarrhea (adjunct)250–500 mg twice daily

Always consult a healthcare provider for personalized dosing.

Potential Side Effects

Gas, bloating; contraindicated in immunocompromised patients (fungal infection risk)

Who Should Avoid It

  • Immunocompromised patients (risk of fungemia)
  • Central venous catheters (yeast translocation risk)
  • Critically ill ICU patients
  • Concurrent systemic antifungal therapy (will kill the yeast)
  • Known yeast allergy

Pregnancy & Lactation

Limited direct pregnancy safety data, though no adverse events have been reported. S. boulardii does not colonize permanently and is not absorbed systemically. Consult a healthcare provider before use during pregnancy or lactation.

Known Drug Interactions

Not affected by antibiotics (unlike bacterial probiotics); antifungals will eliminate it

Evidence Classification

Strong Evidence

Supported by randomized controlled trials (RCTs), systematic reviews, or meta-analyses published in peer-reviewed journals.

Frequently Asked Questions

Can I take S. boulardii during antibiotic treatment?

Yes — this is its primary advantage over bacterial probiotics. S. boulardii is a yeast, not a bacterium, so antibacterial antibiotics do not affect it. Start S. boulardii with the antibiotic course and continue for 1–2 weeks after completion.

Is S. boulardii the same as baker's yeast?

S. boulardii is classified as a subspecies of S. cerevisiae (baker's/brewer's yeast) but is genetically distinct with different metabolic and probiotic properties. It grows optimally at 37°C (body temperature) versus S. cerevisiae's 30°C preference, and has unique enzymatic and immunological activities.

How long does S. boulardii stay in the gut?

S. boulardii does not permanently colonize. It reaches steady-state levels within 3 days and is cleared from the GI tract within 3–5 days after discontinuation. Continuous supplementation is needed for ongoing benefits.

Can immunocompromised patients take S. boulardii?

No. There are documented cases of fungemia (bloodstream yeast infection) in severely immunocompromised patients and those with central venous catheters. It is contraindicated in these populations.

Does S. boulardii help with IBS?

Some studies show improvement in IBS-D (diarrhea-predominant IBS), particularly for stool frequency and consistency. The evidence is not as strong as for antibiotic-associated diarrhea, but S. boulardii may be a useful adjunct in IBS management.

References

  1. Systematic review and meta-analysis of Saccharomyces boulardii in adult patients. McFarland LV. World Journal of Gastroenterology (2010)View study
  2. Treatment of recurrent Clostridium difficile colitis with vancomycin and Saccharomyces boulardii. Surawicz CM, McFarland LV, Greenberg RN, et al.. Clinical Infectious Diseases (2000)View study
  3. Effectiveness of Saccharomyces boulardii in acute diarrhea in children: meta-analysis. Szajewska H, Skórka A. Alimentary Pharmacology & Therapeutics (2009)View study

Related Health Conditions

Related Supplements

Have questions about Saccharomyces boulardii?

Ask Mother Nature AI about dosing, interactions with your medications, whether it fits your health goals, and more — personalized to your health profile.

This entry is for educational purposes only. It is not medical advice. Always consult a qualified healthcare provider before starting, stopping, or changing any supplement regimen, especially if you take medications or have health conditions.